Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients

NCT07287189 is registered in ClinicalTrials.gov with Satellos Bioscience, Inc. as lead sponsor.

NCT NCT07287189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07287189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients
Lead sponsor
Satellos Bioscience, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 8, 2025
Completion date
February 28, 2028
Enrollment
51 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

dmd, duchenne, duchenne muscular dystrophy, muscular dystrophies, neuromuscular diseases